The Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR) Training (Career Development) Component will use CEGIR resources and opportunities available at each site to create a program that will train new investigators in clinical and translational research, designed to ultimately enhance the likelihood of academic success for the investigators in training. This consortium represents an unparalleled opportunity for new clinical investigators to obtain training in the rare diseases eosinophilic esophagitis (EoE), eosinophilic gastritis (EG), and eosinophilic colitis (EC) and to enhance their career development. Each CEGIR site has experience and resources to aid career development of new investigators in clinical investigation and translational research and has new investigators that would be outstanding CEGIR Trainee candidates. The specific goals ofthe CEGIR Training (Career Development) Component are 1) to enable CEGIR Trainees to become independent clinical and/or translational investigators; 2) to aid CEGIR Trainees in developing a broad understanding ofthe basic, translational, and clinical science pertinent to the immunobiology, pathogenesis, and genetics of EoE, EG, and EC via didactic instruction; and 3) to facilitate CEGIR Trainee networking and integration in the EoE, EG, and EC research community. These goals will be achieved through a variety of important interventions including recruiting stellar candidates, encouraging inclusion of underrepresented minorities, didactic lectures, the Biannual CEGIR Education Symposium, interactions with established researchers and patient advocacy groups (PAGs) in EoE, EG, and EC, opportunities to visit centers of excellence to learn new techniques, and active involvement in other research activities of CEGIR.
Increasing the number and quality of clinician researchers studying eosinophilic esophagitis, eosinophilic gastritis, and eosinophilic colitis will improve current and future patient care. We will train clinician researchers about these rare diseases while enhancing the understanding and treatment of them throughout the community. Ultimately, this training is designed to improve patient outcomes while advancing the development of a cure.
| Philpott, Hamish; Dellon, Evan S (2018) The role of maintenance therapy in eosinophilic esophagitis: who, why, and how? J Gastroenterol 53:165-171 |
| Hill, David A; Grundmeier, Robert W; Ramos, Mark et al. (2018) Eosinophilic Esophagitis Is a Late Manifestation of the Allergic March. J Allergy Clin Immunol Pract 6:1528-1533 |
| Safroneeva, Ekaterina; Straumann, Alex; Schoepfer, Alain M (2018) Latest Insights on the Relationship Between Symptoms and Biologic Findings in Adults with Eosinophilic Esophagitis. Gastrointest Endosc Clin N Am 28:35-45 |
| Muir, Amanda; Moore, Hillary; Spergel, Jonathan (2018) To treat or not to treat: The minimally symptomatic EoE patient. Ann Allergy Asthma Immunol : |
| Naramore, Sara; Gupta, Sandeep K (2018) Nonesophageal Eosinophilic Gastrointestinal Disorders: Clinical Care and Future Directions. J Pediatr Gastroenterol Nutr 67:318-321 |
| Steinbach, Erin C; Hernandez, Michelle; Dellon, Evan S (2018) Eosinophilic Esophagitis and the Eosinophilic Gastrointestinal Diseases: Approach to Diagnosis and Management. J Allergy Clin Immunol Pract 6:1483-1495 |
| Spergel, Jonathan; Aceves, Seema S (2018) Allergic components of eosinophilic esophagitis. J Allergy Clin Immunol 142:1-8 |
| Hill, David A; Spergel, Jonathan M (2018) Is eosinophilic esophagitis a member of the atopic march? Ann Allergy Asthma Immunol 120:113-114 |
| Spergel, Jonathan M; Dellon, Evan S; Liacouras, Chris A et al. (2018) Summary of the updated international consensus diagnostic criteria for eosinophilic esophagitis: AGREE conference. Ann Allergy Asthma Immunol 121:281-284 |
| Wechsler, Joshua B; Hirano, Ikuo (2018) Biological therapies for eosinophilic gastrointestinal diseases. J Allergy Clin Immunol 142:24-31.e2 |
Showing the most recent 10 out of 103 publications
